Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

In February, the National Institutes of Health (NIH) announced a cut of “indirect expenses” in its funding for research ...

The Tufts Center for the Study of Drug Development (Tufts CSDD) is conducting new research aimed at understanding how study ...

Mats Sundgren, PhD, senior industry science director, European Institute for Innovation through Health Data (i-HD), discusses how the integration of artificial intelligence, real-world data, and ...